KING OF PRUSSIA, PA — SEED Therapeutics Inc. presented compelling developments from its cancer research programs at the 2025 Annual Meeting of the American Association for Cancer Research (AACR) in Chicago. The company’s cutting-edge RITE3™ platform has yielded promising results in addressing challenging cancer targets, with significant advancements in both Ewing sarcoma treatment and KRAS G12D degradation.
Highlighting their innovative RBM39 degrader, SEED revealed remarkable preclinical results. The compound ST-00937 effectively degrades RBM39 to undetectable levels, inducing complete tumor regression in Ewing sarcoma models within two weeks. SEED plans to file an Investigational New Drug (IND) application for its next-generation RBM39 degrader by mid-2025.
“We are proud of the rapid advancement of our potentially best-in-class RBM39 degrader toward clinical trials,” said Lan Huang, Ph.D., Co-Founder, Chair, and CEO of SEED Therapeutics. “This progress represents our commitment to addressing urgent therapeutic gaps, particularly in aggressive cancers like Ewing sarcoma.”
SEED also presented a novel dual PROTAC approach that targets KRAS G12D, overcoming the “hook effect” that limits current monotherapy PROTAC treatments. By leveraging two PROTACs with different E3 ligases, researchers achieved enhanced degradation of KRAS G12D and improved apoptosis in pancreatic cancer models.
“In combining two PROTACs using different E3 ligases to eliminate the hook effect, we pursued an unanticipated observation that led to a groundbreaking finding,” said James Tonra, Ph.D., President and Chief Scientific Officer of SEED Therapeutics.
SEED’s presentations solidify its position at the forefront of targeted cancer therapies, with collaborations involving prestigious institutions like Dana-Farber and the University of Pennsylvania. These advancements offer new hope for tackling previously undruggable cancer targets and redefining treatment options.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.